Your session is about to expire
← Back to Search
Other
Multiple Treatments for Chronic Pain (CPMP Trial)
Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study
Have a history of daily pain for at least 12 weeks based on participant report or medical history
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, up to week 8
Awards & highlights
CPMP Trial Summary
This trial compares different treatments for long-term chronic pain, with independent plans for each treatment and an overarching structure for the study.
Who is the study for?
This trial is for adults with chronic pain from conditions like osteoarthritis or diabetic neuropathy, who've had daily pain for at least 12 weeks. Participants must be willing to stop all other pain meds except emergency ones, not start new therapies during the study, have a BMI under 40 kg/m², and score specific values on pain scales.Check my eligibility
What is being tested?
The study tests multiple interventions (LY3857210 ISA, LY3526318 ISA, etc.) against placebos to manage chronic pain. It's designed to allow each intervention-specific appendix (ISA) to begin independently as they become ready for clinical trials within an overarching protocol.See study design
What are the potential side effects?
Potential side effects are not specified but may include typical drug-related reactions such as nausea, headaches, dizziness or allergic responses. The exact side effects will depend on the individual drugs being tested in each intervention group.
CPMP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am willing to stop my chronic pain medications except for emergency use during the study.
Select...
I have experienced daily pain for at least 12 weeks.
CPMP Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, up to week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, up to week 8
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants Who Were Allocated to Each ISA
CPMP Trial Design
12Treatment groups
Experimental Treatment
Group I: LY3857210 Osteoarthritis ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3857210 or matching placebo
Group II: LY3857210 Diabetic Neuropathic Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3857210 or matching placebo
Group III: LY3857210 Chronic Back Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3857210 or matching placebo
Group IV: LY3556050 Osteoarthritis ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3556050 or matching placebo
Group V: LY3556050 Diabetic Neuropathic Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3556050 or matching placebo
Group VI: LY3556050 Chronic Back Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3556050 or matching placebo
Group VII: LY3526318 Osteoarthritis ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3526318 or matching placebo
Group VIII: LY3526318 Diabetic Neuropathic Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3526318 or matching placebo
Group IX: LY3526318 Chronic Back Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3526318 or matching placebo
Group X: LY3016859 Osteoarthritis ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3016859 or matching placebo
Group XI: LY3016859 Diabetic Neuropathic Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3016859 or matching placebo
Group XII: LY3016859 Chronic Back Pain ISAExperimental Treatment2 Interventions
Participants are randomized to receive either active LY3016859 or matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo Oral
2014
Completed Phase 3
~110
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,620 Previous Clinical Trials
3,206,599 Total Patients Enrolled
25 Trials studying Osteoarthritis
5,380 Patients Enrolled for Osteoarthritis
Study DirectorEli Lilly and Company
1,348 Previous Clinical Trials
405,745 Total Patients Enrolled
10 Trials studying Osteoarthritis
2,293 Patients Enrolled for Osteoarthritis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had a problem with alcohol, illegal drugs, or pain medicines in the past 2 years.I have not had any cancer except for skin cancer that was removed, in the last 2 years.I have a serious heart rhythm problem.Your pain level, as measured on a scale, falls between 40 and 95.I've had a procedure in the last 6 months to permanently reduce feeling in a specific area.Your body mass index is less than 40 kg/m².I have been diagnosed with fibromyalgia.Your score on the pain catastrophizing scale is 30 or lower.I will continue my current non-drug pain treatments without starting new ones during the study.You have a problem with using drugs or alcohol as defined by the DSM-5.You have tested positive for HIV.I am willing to stop my chronic pain medications except for emergency use during the study.I am scheduled for surgery during the study, regardless of the reason.I have experienced daily pain for at least 12 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: LY3857210 Osteoarthritis ISA
- Group 2: LY3016859 Osteoarthritis ISA
- Group 3: LY3016859 Diabetic Neuropathic Pain ISA
- Group 4: LY3556050 Osteoarthritis ISA
- Group 5: LY3556050 Chronic Back Pain ISA
- Group 6: LY3526318 Diabetic Neuropathic Pain ISA
- Group 7: LY3526318 Osteoarthritis ISA
- Group 8: LY3526318 Chronic Back Pain ISA
- Group 9: LY3857210 Chronic Back Pain ISA
- Group 10: LY3016859 Chronic Back Pain ISA
- Group 11: LY3556050 Diabetic Neuropathic Pain ISA
- Group 12: LY3857210 Diabetic Neuropathic Pain ISA
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
At how many sites is this experiment taking place?
"The scope of this medical trial has expanded and is now recruiting patients from 26 different locations. These include Jacksonville, Miami, Ocala as well as other cities. To reduce the travel burden for participants, it is advised to select a clinic that is in close proximity."
Answered by AI
What is the number of participants involved in this clinical experiment?
"This trial necessitates that 10,000 individuals conforming to the specified criteria become participants. Encore Research Group- Jacksonville Center for Clinical Research in Florida and Suncoast Research Group in Georgia are two of many sites where patients can enroll."
Answered by AI
Is the LY3016859 Osteoarthritis ISA drug regimen sanctioned by the FDA?
"Using our 1 to 3 scale, LY3016859 Osteoarthritis ISA received a score of 2 due to its Phase 2 status; meaning although there is some safety data present, no efficacy has been documented yet."
Answered by AI
Are there still open positions in this research project?
"Affirmative. According to the data posted on clinicaltrials.gov, this scientific study is actively recruiting participants and was initially announced on January 30th 2020 with a last update around August 1st 2023. From 26 sites across the world, 10000 people are sought for inclusion in the trial."
Answered by AI
Who else is applying?
What state do they live in?
Massachusetts
What site did they apply to?
University of Miami Don Suffer Clinical Research Building
North Georgia Clinical Research
MedVadis Research Corporation
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Why did patients apply to this trial?
In pain all the time. I have only used Naproxin and Ibuprofen. NEITHER is effective.
PatientReceived no prior treatments
I am hoping something positive will come out during the study for myself and others.
PatientReceived 1 prior treatment
Numbness and pain goes up to my ankles and shins sometimes.. affects my walking and sleep.
PatientReceived 1 prior treatment
I have had pain and have try chiropractors and PT and I still have it. It may also help someone else too.
PatientReceived 1 prior treatment
What questions have other patients asked about this trial?
What is the compensation?
PatientReceived 2+ prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger